Hysingla ER is a prescription opioid pain medication containing hydrocodone bitartrate in an extended-release tablet. It is FDA-approved for managing severe pain that requires daily, around-the-clock opioid treatment over a long period, and only when other pain management options have not worked well enough. It is not designed for occasional or as-needed pain relief.
How Hysingla ER Works
Hydrocodone, the active ingredient in Hysingla ER, is a semi-synthetic opioid that primarily targets mu-opioid receptors in the brain and spinal cord. When it binds to these receptors, it changes the way your nervous system processes pain signals, reducing how much pain you feel. This same receptor activity is also responsible for the side effects common to all opioids, including feelings of euphoria, slowed breathing, and physical dependence over time.
The “ER” stands for extended release. Unlike immediate-release hydrocodone products (like those combined with acetaminophen), Hysingla is formulated to release the medication slowly throughout the day. This means you take it once every 24 hours rather than every four to six hours. The tablet is also physically designed to be harder to crush, break, or dissolve, which helps reduce the risk of tampering for misuse.
Who Hysingla ER Is Prescribed For
Hysingla is reserved for people whose pain is severe enough that they need continuous opioid treatment and who have already tried other approaches. Those alternatives include non-opioid pain relievers and shorter-acting opioid medications. If those options were ineffective, poorly tolerated, or simply not enough, Hysingla may be considered.
This is not a first-line pain medication. The FDA label specifically notes that the risks of addiction, misuse, overdose, and death are greater with extended-release opioid formulations compared to shorter-acting ones, so prescribers are expected to exhaust other options first.
Available Strengths and Dosing
Hysingla ER comes in seven tablet strengths: 20, 30, 40, 60, 80, 100, and 120 mg. For someone who has not been taking opioids regularly, the starting dose is 20 mg taken once every 24 hours. People already taking opioids may be switched to a higher dose based on what they were previously using, though prescribers typically start conservatively and adjust upward if needed.
The tablets must be swallowed whole. Cutting, crushing, chewing, or dissolving them destroys the extended-release mechanism, which could release a dangerously large amount of hydrocodone all at once.
Common Side Effects
Hysingla shares the side effect profile typical of opioid medications. The most frequently reported effects in clinical trials include constipation, nausea, fatigue, dizziness, headache, and vomiting. Constipation is particularly persistent with long-term opioid use because opioids slow down the digestive tract, and unlike some other side effects, the body does not develop tolerance to it over time.
Drowsiness and dizziness are common when first starting the medication or after a dose increase. These effects typically lessen as your body adjusts, but they can impair your ability to drive or operate machinery, especially early in treatment.
Serious Risks
Hysingla carries the FDA’s most serious safety warning, a boxed warning, for several reasons:
- Addiction and dependence: Even at prescribed doses, opioids carry a risk of addiction. Physical dependence, where your body adapts to the drug and you experience withdrawal symptoms if you stop suddenly, develops with regular use and is a separate issue from addiction, though the two can overlap.
- Respiratory depression: Opioids slow breathing by acting directly on the brain’s breathing centers. This is the primary way opioid overdoses become fatal. The risk is highest when starting Hysingla, after a dose increase, or if taken with other substances that also suppress breathing.
- Dangerous interactions with alcohol and sedatives: Combining Hysingla with alcohol, benzodiazepines (anti-anxiety medications), or other central nervous system depressants can cause dangerously slowed breathing, extreme sedation, coma, or death.
- Accidental ingestion: A single dose of Hysingla can be fatal to someone, particularly a child, who is not accustomed to opioids. The high-strength tablets (60 mg and above) pose an especially serious risk.
Who Should Not Take Hysingla
Hysingla is contraindicated in people with severe asthma or significant breathing problems, particularly in settings where monitoring is not available. It should also not be used by anyone with a known bowel obstruction, including a condition called paralytic ileus where the intestines stop moving food through normally. People with a known hypersensitivity to hydrocodone should avoid it as well.
Anyone currently taking or recently using a type of antidepressant called a monoamine oxidase inhibitor (MAOI) should not take Hysingla, as the combination can cause dangerous reactions.
Stopping Hysingla Safely
If you have been taking Hysingla regularly, stopping abruptly can trigger withdrawal symptoms including muscle aches, restlessness, anxiety, sweating, nausea, diarrhea, and insomnia. These symptoms are uncomfortable but generally not life-threatening. The standard approach is a gradual dose reduction, or taper, to minimize withdrawal effects. Your prescriber will typically decrease the dose in small steps over days or weeks depending on how long you have been taking it and at what dose.
How Hysingla Differs From Other Hydrocodone Products
Most people encounter hydrocodone in combination products that pair it with acetaminophen or ibuprofen for short-term pain relief. Those are immediate-release formulations taken every four to six hours. Hysingla contains only hydrocodone with no added pain reliever, and its extended-release design means one tablet covers a full 24-hour period. This makes it suited for chronic pain rather than the short-term pain after a dental procedure or minor injury.
The once-daily dosing can simplify a pain management routine, but the tradeoff is a higher-strength medication with greater risks. The tamper-resistant formulation provides a layer of safety by maintaining some of its slow-release properties even if the tablet is physically damaged, though no formulation is completely abuse-proof.